Birgitt Schönfisch

Birgitt Schönfisch

Auto-generated profile, based on publicly available information

Birgitt Schönfisch

Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MWMarkus Wallwiener
Markus Wallwiener
AHAndreas Hartkopf
Andreas Hartkopf
SRSabine Riethdorf
Sabine Riethdorf
JNJuliane Nees
Juliane Nees
MSMartin Ronald Sprick
Martin Ronald Sprick
ASAndreas Schneeweiss
Andreas Schneeweiss
In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help to optimize MBC treatment. While tissue sampling is invasive and often difficult to repeat, circulating tumor cell (CTC) analysis requires only a blood sample and might provide an easy-to-repeat, real-time “liquid biopsy” approach. The present retrospective study was conducted to compare HER2 expression in primary tumors, metastatic tissue, and circulating tumor cells (CTCs) from MBC patients and to analyze the potential impact of HER2 overexpression by CTCs on progression-free (PFS) and overall survival (OS) in MBC. CTC-positive (five or more CTCs/7.5 mL blood; CellSearch®, Janssen Diagnostics) MBC patients starting a new line of systemic treatment were eligible for the study. HER2 status of CTCs was determined by immunofluorescence (CellSearch®). HER2 status of primary (PRIM) and metastatic (MET) tumor tissue was determined by immunohistochemistry. Data were analyzed using descriptive statistics and Kaplan–Meier plots. One hundred seven patients (median age (range) 57 (33–81) years) were included. 100/107 (93 %) patients were followed-up for a median [95 % confidence interval (CI)] of 28.5 [25.1–40.1] months. Of 37/107 (35 %) CTC-HER2-positive patients only 10 (27 %) were PRIM-HER2-positive. 6/46 (13 %) patients were MET-HER2-positive; only 2/10 (20 %) CTC-HER2-positive patients were MET-HER2-positive. Overall accuracy between CTC-HER2 expression and PRIM-HER2 and MET-HER2 status was 69 % and 74 %, respectively. Kaplan–Meier plots of PFS and OS by CTC-HER2 status revealed significantly longer median [95 % CI] PFS of CTC-HER2-positive versus CTC-HER2-negative patients (7.4 [4.7–13.7] versus 4.34 [3.5–5.9] months; p = 0.035). CTC-HER2-positive status showed no significant difference for OS (13.7 [7.7–30.0] versus 8.7 [5.9–15.3] months; p = 0.287). HER2 status can change during the course of breast cancer. CTC phenotyping may serve as an easy-to-perform “liquid biopsy” to reevaluate HER2 status and potentially guide treatment decisions. Further, prospective studies are needed.

11 July 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MWMarkus Wallwiener
Markus Wallwiener
SRSabine Riethdorf
Sabine Riethdorf
AHAndreas Hartkopf
Andreas Hartkopf
CMCaroline Modugno
Caroline Modugno
JNJuliane Nees
Juliane Nees
ASAndreas Schneeweiss
Andreas Schneeweiss
To prospectively assess circulating tumor cell (CTC) status at baseline (CTCBL) and after one cycle of a new line of systemic therapy (CTC1C), and changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) for their utility in predicting response, progression-free (PFS) and overall survival (OS) in metastatic breast cancer (MBC). CTCBL and CTC1C status was determined as negative (-) or positive (+) for < 5 or ≥ 5 CTCs/7.5 ml blood using CellSearch™ (Veridex). CTCKIN was categorized as favorable (CTC1C-) or unfavorable (CTC1C+). Tumor response was to be assessed every 2–3 months using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Statistical analysis focused on the relation between CTC status and CTCKIN, and response, PFS, and OS. 133/393 (34%) patients enrolled were CTCBL+. CTC1C status after one cycle and radiological tumor response were assessed after median (range) periods of 1.2 (0.5–3.2) and 2.9 (0.5–4.8) months, respectively. 57/201 (28%) were CTC1C+. Median [95% confidence interval] PFS and OS (months) were significantly reduced in CTCBL+ vs. CTCBL- patients (PFS 4.7 [3.7–6.1] vs. 7.8 [6.4–9.2]; OS 10.4 [7.9–15.0] vs. 27.2 [22.3–29.9]), and for CTC1C+ vs. CTC1C- patients (PFS 4.3 [3.6–6.0] vs. 8.5 [6.6–10.4]; OS 7.7 [6.4–13.9] vs. 30.6 [22.6–not available]). Unfavorable CTCKIN was significantly associated with progressive disease. Multivariate Cox regression analysis revealed prognostic factors for shorter PFS (CTCBL+, persistent CTCs after one cycle, ≥ 3rd-line therapy, and triple-negative receptor status) and shorter OS (CTCBL+, persistent CTCs after one cycle, bone-and-visceral/local metastases, ≥ 3rd-line therapy, and triple-negative receptor status). CTCBL, CTC1C, and CTCKIN are predictive of outcome in MBC. Serial CTC enumeration is useful in tailoring systemic treatment of MBC. Not applicable.

1 January 2011 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
Katharina K. RallKatharina K. Rall
Katharina K. Rall
GBGianmaria Barresi
Gianmaria Barresi
MWMichael H. Walter
Michael H. Walter
SPSven Poths
Sven Poths
KHKarina Haebig
Karina Haebig
SBSara Yvonne Brucker
Sara Yvonne Brucker
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is present in at least 1 out of 4,500 female live births and is the second most common cause for primary amenorrhea. It is characterized by vaginal and uterine aplasia in an XX individual with normal secondary characteristics. It has long been considered a sporadic anomaly, but familial clustering occurs. Several candidate genes have been studied although no single factor has yet been identified. Cases of discordant monozygotic twins suggest that the involvement of epigenetic factors is more likely.

1 February 2017 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
FGFriederike Grevenkamp
Friederike Grevenkamp
FKFelix Kommoss
Felix Kommoss
FKFriedrich Kommoss
Friedrich Kommoss
SLSigurd Lax
Sigurd Lax
Falko FendFalko Fend
Falko Fend
SKStefan Kommoss
Stefan Kommoss

1 October 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TDThomas M Deutsch
Thomas M Deutsch
SRSabine Riethdorf
Sabine Riethdorf
JNJuliane Nees
Juliane Nees
AHAndreas Hartkopf
Andreas Hartkopf
BSBirgitt Schönfisch
Birgitt Schönfisch
MWMarkus Wallwiener
Markus Wallwiener

21 August 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CWChristian W. Wallwiener
Christian W. Wallwiener
MWMarkus Wallwiener
Markus Wallwiener
RKRalf R. Kurth
Ralf R. Kurth
CRCarmen Röhm
Carmen Röhm
HNHans Neubauer
Hans Neubauer
TFTanja Fehm
Tanja Fehm